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AbsTrACT
background Stunting is the most common 
manifestation of childhood undernutrition worldwide. 
Children presenting with severe acute malnutrition 
(SAM) are often also severely stunted. We evaluated 
linear growth and its determinants after medically 
complicated SAM.
Methods We performed secondary analysis of 
clinical trial data (NCT00934492) from HIV-uninfected 
Kenyan children aged 2–59 months hospitalised with 
SAM. Outcome was change in height/length-for-age 
z-score (HAZ) between enrolment and 12 months later. 
Exposures were demographic, clinical, anthropometric 
characteristics and illness episodes during follow-up.
results Among 1169 children with HAZ values at 
month 12 (66% of those in original trial), median (IQR) 
age 11 (7–17) months and mean (SD) HAZ −2.87 
(1.6) at enrolment, there was no change in mean HAZ 
between enrolment and month 12: −0.006Z (95% CI 
−0.07 to 0.05Z). While 262 (23%) children experienced 
minimal HAZ change (within ±0.25 HAZ), 472 (40%) 
lost >0.25 and 435 (37%) gained >0.25 HAZ. After 
adjusting for regression to the mean, inpatient or 
outpatient episodes of diarrhoea and inpatient severe 
pneumonia during follow-up were associated with 
HAZ loss. Premature birth and not being cared by 
the biological parent were associated with HAZ gain. 
Increases in mid-upper arm circumference and weight-
for-age were associated with HAZ gain and protected 
against HAZ loss. Increase in weight-for-height was not 
associated with HAZ gain but protected against HAZ 
loss. No threshold of weight gain preceding linear catch-
up growth was observed.
Conclusions Interventions to improve dietary quality 
and prevent illness over a longer period may provide 
opportunities to improve linear growth.
InTrOduCTIOn
Stunting (defined as height/length-for-age z-score 
(HAZ) ≤2 using WHO 2006 growth reference 
standards) is the most prevalent form of under-
nutrition: 151 million children under 5 years old 
were stunted in 2017.1–4 A Sustainable Develop-
ment Goal has been set by the United Nations to 
reduce the proportion of children who are stunted 
worldwide by 40% by 2025.5 More than 90% of 
stunted children live in Africa and Asia.1 In Kenya, 
26% of under-5s were stunted in 2014,6 with 
wide subnational variation, ranging from 15% in 
central Kenya to 46% on the coast.6 7 Stunting is 
considered to be a result of chronic malnutrition, 
exacerbated by frequent infections, especially diar-
rhoea.8 9 In resource-poor countries, it is estimated 
that approximately a fifth of stunting occurs in utero 
and continues up to 2 years of age.10 Being stunted 
is associated with reduced cognitive development 
and adult productivity, adverse maternal repro-
ductive outcomes and risks of non-communicable 
diseases in adulthood.3 11–13 Despite being globally 
recognised as the most frequent form of undernu-
trition, stunting is often overlooked in the clinic 
because length/height is not routinely measured in 
health facilities in affected countries, some commu-
nities consider short stature as ‘normal’, and specific 
effective interventions are lacking.3 
An overview of published clinical trials among 
children with severe acute malnutrition (SAM) 
reveals that they are also usually severely stunted, 
thus their malnutrition is not only acute (listed 
in online supplementary table 1).14 15 The main 
target of treatment and nutritional rehabilitation of 
complicated SAM is to increase body weight and/
or mid-upper arm circumference (MUAC).16–18 It 
What is already known on this topic?
 ► Children presenting with severe acute 
malnutrition (SAM) are usually also severely 
stunted suggesting that their malnutrition is 
often not only acute.
 ► Several studies have reported minimal average 
height/length-for-age z-score (HAZ) gain during 
recovery from SAM despite intense nutritional 
support and weight gain.
 ► A threshold of wasting recovery before linear 
catch-up growth has previously been proposed.
What this study adds?
 ► Despite an insignificant change in mean 
HAZ subgroups of children gained or lost HAZ 
beyond that predicted by regression to the 
mean.
 ► No threshold of wasting recovery preceding 
linear catch-up growth was observed.
 ► More active prevention and treatment of 
illness following SAM treatment may provide 
opportunities to improve linear growth.
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might therefore be expected that such intervention would also 
impact on linear growth. However, clinical trials of treatment 
for SAM in Asia and Africa demonstrate that children with SAM 
have little or no change in average HAZ following treatment 
(online supplementary table 1).19–23 In one study of 369 predom-
inantly oedematous Jamaican children recovering from severe 
malnutrition, Walker et al observed that in a subgroup who were 
more severely stunted and mostly non-oedematous, weight gain 
preceded catch-up in linear growth and proposed that reaching 
a threshold of weight-for-height/length z-scores (WHZ) of −1.3 
was required before linear catch-up growth could begin.24
We therefore evaluated linear growth and its associated 
factors among HIV-uninfected children enrolled in a multicentre 
randomised clinical trial during recovery from complicated SAM 
and followed up for 12 months.23
PATIenTs And MeThOds
study design and setting
We performed a secondary analysis of data from a double-
blinded, randomised placebo-controlled trial ( ClinicalTrials. gov 
NCT00934492).23 The original trial was designed to determine 
the efficacy of daily co-trimoxazole prophylaxis in reducing 
postdischarge mortality among children with complicated SAM. 
The intervention had no overall effect on linear growth.23
The trial recruited children from paediatric wards of four 
Kenyan hospitals while receiving treatment for complicated 
SAM: Mbagathi County Hospital (Nairobi), Coast General 
Hospital (Mombasa), Kilifi County Hospital and Malindi 
Subcounty Hospital.
study population
The original trial recruited children aged 2–59 months, hospital-
ised with complicated SAM defined as: MUAC <11 cm for chil-
dren <6 months, MUAC <11.5 cm for children 6–59 months, 
or oedema at any age.23 Children were excluded if they had 
positive HIV rapid antibody test, because they were already 
recommended to receive daily co-trimoxazole prophylaxis, or 
had known hypersensitivity to co-trimoxazole. Children were 
enrolled into the trial after the initial ‘stabilization’ phase of 
SAM inpatient treatment and caregiver consent was provided.18 
Participants were scheduled to attend clinic visits monthly after 
study enrolment up to month 6 and thereafter, every 2 months 
up to month 12, giving a total of 1-year follow-up.
study outcomes
The main study outcome was change in HAZ between study 
enrolment and month 12. The exposures of interest were age, 
gender, recruitment site, gain in weight-for-age z-score (WAZ), 
WHZ and MUAC, clinical variables at enrolment, randomisation 
arm and illness episodes occurring during follow-up.
data sources and measurements
At enrolment, clinical history, disease signs and sociodemo-
graphic data were collected. During enrolment and at every 
scheduled visit, length (or height for children ≥24 months old), 
weight and MUAC were measured and documented.23
During follow-up, hospital readmissions and illness episodes 
treated as an outpatient were prospectively documented. Study 
staff visited the homes of children failing to attend scheduled 
visits. During these home visits, vital status was assessed and 
MUAC measured, but weight and height were not measured 
because of the measurement equipment required.
study size
We used data from all (n=1169) participants who (1) survived, 
(2) remained in the 1-year follow-up, and (3) had their HAZ 
measured at study end.
statistical methods
All analyses were conducted using Stata V.15.1 (StataCorp, 
College Station, TX, USA). HAZ, WHZ and WAZ were calcu-
lated using the 2006 WHO growth reference. Change in 
HAZ between enrolment and month 12 was categorised into 
three groups: minimal change in HAZ of −0.25 to 0.25; loss 
of HAZ >0.25; and gain in HAZ >0.25 according to Walker 
and Golden.24 We hypothesised that gain or loss of HAZ may 
be associated with different baseline factors and these were 
thus analysed as separate outcomes using the minimal change 
group as the reference. To evaluate the effect of regression to the 
mean (RTM), gain or loss of HAZ was adjusted for the differ-
ence between individuals’ HAZ values and the group mean HAZ 
value at enrolment.25 We used backwards stepwise multinomial 
logistic regression to determine the features associated with 
either loss or gain, retaining variables with p<0.1, and reported 
adjusted coefficients transformed to relative risk ratios with 
p<0.05 in the final model. We also performed a sensitivity anal-
ysis to explore the factors associated with HAZ loss or gain from 
baseline to month 12 among stunted children at baseline only. To 
determine the extent to which overall changes in weight, WAZ, 
WHZ and MUAC were associated with HAZ changes during 
follow-up, we calculated the Spearman’s rank correlation coef-
ficient after excluding children with oedema at enrolment, and 
examined other factors associated with change in HAZ using 
multinomial logistic regression.
To look for evidence that a curve indicating inflection or 
threshold characterised the relationship between changes in 
HAZ and changes in weight, WAZ, WHZ and MUAC rather than 
a straightforward linear relationship, we performed multivari-
able fractional polynomial regression (MFPR) adjusted for age, 
gender, study site and randomisation arm. Regression models 
based on fractional polynomial curves (powers of −2, −1, −0.5, 
0, 0.5, 1, 2, 3) were compared with a linear model by testing 
for difference in deviance using the STATA mfp command. The 
fractional polynomial term was retained if there was significant 
difference in deviance from the linear model.26
To test the threshold proposed by Walker and Golden, we 
compared linear growth among children, including those with 
oedema at enrolment, above and below the threshold of WHZ 
−1.3 or more after 1 month, using a Wilcoxon rank-sum test.24
resulTs
The original trial enrolled 1778 children. We excluded 609 
(34%) children; (257 (14%) died, 56 (3.1%) were lost to 
follow-up, 36 (2.0%) voluntarily withdrew and 260 (15%) had 
no HAZ measured at month 12). Thus, 1169 children were 
included in this analysis, median (IQR) age at enrolment was 
11 (7 ̶ 17) months, and 565 (48%) were girls (table 1). Mean 
(SD) HAZ at enrolment was −2.87 (1.6). Overall, 358 (31%), 
290 (25%) and 521 (44%) were not stunted, moderately and 
severely stunted, respectively (online supplementary table 2 and 
online supplementary figure 1). Baseline stunting was associ-
ated with older age, female sex, recruitment hospital, reported 
low birth weight, presence of oedema and lower MUAC (online 
supplementary tables 3 and 4). Children who were excluded had 
similar enrolment characteristics, but a higher frequency of post-
discharge illness episodes (under follow-up events in table 1).
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The largest monthly change in HAZ was from enrolment to 
month 1, a drop (SD) of 0.20 (0.5) z-scores (online supplemen-
tary table 3, online supplementary figures 2 and 3). After month 
1, mean (SD) HAZ rose to −2.94 (1.4) at month 4 and there-
after plateaued to month 12. In contrast, during the first month, 
WAZ, WHZ and MUAC (cm) had their largest gains (online 
supplementary table 5 and online supplementary figure 2).
At month 12, the mean (SD) HAZ was −2.88 (1.4), a change 
(SD) of −0.006 (1.1) since enrolment (figure 1 and online 
supplementary table 5). WAZ, WHZ and MUAC at month 12 
had increased (SD) since enrolment by 1.46 (1.2), 1.94 (1.5) and 
2.83 (1.4) cm, respectively (figure 1, online supplementary table 
5 and online supplementary figure 2).
Of the 1169 children, 262 (23%) had minimal change in HAZ 
from enrolment to month 12, while 472 (40%) lost >0.25 and 
435 (37%) gained >0.25 z-scores (online supplementary table 
6). Most children (744/1169; 64%) were in the same HAZ cate-
gory (severely, moderately or not stunted) at month 12 as they 
had been at study enrolment (online supplementary table 2 and 
online supplementary figure 1).
Features associated with changes in hAZ
The youngest and oldest children had the largest change in HAZ, 
giving age a skewed U-shaped association (p<0.001 compared 
with a linear fit) (online supplementary figure 4). Age <12 
months was associated with losing HAZ in the univariate anal-
ysis (online supplementary table 7).
In the multivariate analyses, losing HAZ was associated with 
postdischarge outpatient treatment for diarrhoea, hospital 
Table 1 Study participants’ profile at time of enrolment and follow-up
All participants in primary trial (n=1778)
Participants assessed at month 12 and included 
in the secondary analysis (n=1169)
Demographics at study enrolment
  Age in months, median (IQR) 11 (7–16) 11 (7–17)
  Sex, female 875 (49) 565 (48)
  Born prematurely* 221 (12) 141 (12)
  Born underweight† 362 (20) 229 (20)
  Main caregiver-biological mother 1661 (93) 1088 (93)
  Randomised to co-trimoxazole prophylaxis 887 (50) 597 (51)
  Currently breast feeding 1092 (61) 712 (61)
  Recruitment hospital
   Kilifi County Hospital 151 (8.5) 114 (9.8)
   Coast General Hospital 849 (48) 542 (46)
   Malindi Subcounty Hospital 271 (15) 202 (17)
   Mbagathi County Hospital 507 (29) 311 (27)
Nutritional status at study enrolment
  Oedema 300 (17) 210 (18)
  MUAC (cm), mean±SD 10.6±1.1 10.6±1.0
  HAZ, mean±SD −2.87±1.7 −2.87±1.6
  WAZ, mean±SD −3.99±1.0 −3.96±1.0
  WHZ, mean±SD −3.34±1.3 −3.32±1.2
  Haemoglobin (g/dL), mean±SD 9.9±2.2 9.8±2.3
Index admission diagnosis
  Index admission with diarrhoea 1021 (57) 679 (58)
  Index admission with severe pneumonia 656 (37) 404 (35)
  Index admission with tuberculosis 67 (3.8) 45 (3.9)
  Index admission with clinical signs of rickets 230 (13) 139 (12)
  Index admission with other comorbidities‡ 97 (5.5) 66 (5.7)
Follow-up events
  Outpatient treatment for diarrhoea 653 (37) 329 (28)
  Outpatient treatment for pneumonia 716 (40) 275 (24)
  Outpatient treatment for another diagnosis§ 547 (31) 387 (33)
  Hospital readmission for diarrhoea 218 (12) 102 (8.7)
  Hospital readmission for severe pneumonia 308 (17) 159 (14)
  Hospital readmission for another diagnosis§ 236 (13) 96 (8.2)
  Died 257 (14) – 
  Withdrawn or loss to follow-up 92 (5.2) – 
The results are n (%) except when specified.
WAZ and WHZ exclude children with oedema. Outpatient treatment comprised any treatment offered to the participant either during scheduled or unscheduled follow-up visits. 
*Gestational age <37 weeks.
†Birth weight <2500 g.
‡Comorbidity assessed at study enrolment including 5 sickle cell, 15 heart disease, 38 cerebral palsy, 3 epilepsy and 5 children with both cerebral palsy and epilepsy.
§Diagnoses of malaria, tuberculosis, sepsis, meningitis, measles, anaemia, and urinary tract infection and skin/soft tissue infection.
HAZ, height/length-for-age z-score; MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score; WHZ, weight-for-height/length z-score.
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readmission for diarrhoea and for severe pneumonia, and 
randomisation to co-trimoxazole prophylaxis after adjusting for 
RTM (table 2). Gain in HAZ was associated with the caregiver 
not being the child’s biological mother, reported preterm birth 
and randomisation to co-trimoxazole after adjusting for RTM 
(table 2). Children born preterm had lower HAZ at enrolment 
than other participants (p<0.001), and their HAZ increased (SD) 
during the 1-year period to −3.04 (1.3), which was not signifi-
cantly different from the other children (−2.85 (1.4)) (p=0.06) 
(online supplementary figure 5). In a sensitivity analysis, the 
factors associated with HAZ gain or loss among children who 
were already stunted at enrolment were found to be similar to 
those of the overall cohort (online supplementary table 8).
Changes in weight, WAZ and MUAC between enrolment and 
month 12 had strong positive correlation with absolute change 
in HAZ, while change in WHZ had weak correlation (table 3). 
Overall, there was no evidence from the MFPR analyses of an 
inflection in the association between change in HAZ up to month 
12 and change in weight, WAZ, WHZ or MUAC (figure 2).
At month 1,275 (24%) children were above the threshold 
proposed by Walker and Golden24 of WHZ −1.3. These chil-
dren had fewer baseline comorbidities, were less wasted and 
more stunted at enrolment than children below the threshold 
(online supplementary table 9). Between enrolment and month 
1, children lost approximately 0.2 HAZ irrespective of reaching 
WHZ −1.3 or not (p=0.40) (figure 3 and online supplementary 
table 9). Linear growth between months 1 and 3 was greater 
in children who were above WHZ −1.3 than children below 
this threshold at month 1 (p<0.001). However, from month 
3 to month 12 there were no differences in absolute values or 
changes in HAZ between these two groups (p=0.23) (figure 3 
and online supplementary table 9).
dIsCussIOn
Despite inpatient, medical and nutritional treatment for compli-
cated SAM and subsequent outpatient therapeutic feeding, active 
follow-up to 1 year with access to extra care and referral for 
specialist services where needed by the study team, there was 
no significant average increase in HAZ. This was despite rapid 
weight and MUAC gain.
Previous trials that monitored children recovering from 
SAM in Africa have similarly demonstrated catch-up in weight 
but not in linear growth.20–22 27 In a community-based study in 
Nepal, wasted children gained weight but not height, suggesting 
wasted children experience weight growth at the expense of 
growing length.28 However, severely malnourished children 
in Jamaica experienced increased growth in both weight and 
height, although linear growth tended to occur later than weight 
growth.29 30
Overall, an increase in WHZ was not associated with posi-
tive linear growth in our study and there was no evidence of 
a threshold WAZ or WHZ gain required for a linear growth 
catch-up. When we examined a previously proposed threshold 
of wasting24 in relation to linear growth, we found a short period 
of accelerated linear growth among a subset of children with 
very different baseline characteristics, suggesting that early linear 
growth response predominantly depends on baseline status, such 
as the presence or absence of comorbidities.
Whereas having episodes of diarrhoea during follow-up was 
associated with linear growth deficit, length was not gained by 
not having diarrhoea. This concurs with results from a pooled 
analysis of data from seven studies in the general community that 
found diarrhoea was associated with long-term decrease in linear 
growth.31 Previous studies have also reported other infectious 
diseases such as malaria and respiratory illnesses may be associ-
ated with linear growth faltering.14 We found an association with 
hospital admission for severe pneumonia, but the occurrence of 
malaria was too rare to be included in our analyses separately. 
However, in a multicountry birth cohort in low/middle-income 
Figure 1 Dot plot of change between study enrolment and month 12 
in HAZ, WHZ, WAZ and MUAC (cm). The dashed line (Y=0) indicates no 
change; the horizontal red bars are the respective anthropometry mean 
change. HAZ, height/length-for-age z-score; MUAC, mid-upper arm 
circumference; WAZ, weight-for-age z-score; WHZ, weight-for-height/
length z-score. 
Table 2 Factors associated with loss or gain of HAZ during the 1-year follow-up
demographics at study enrolment
lost at least 0.25 hAZ* Gained at least 0.25 hAZ*
Adjusted rrr 95% CI P values Adjusted rrr 95% CI P values
Main caregiver not the biological mother – – – 2.42 1.19 to 4.92 0.02
Randomised to co-trimoxazole prophylaxis 0.70 0.51 to 0.96 0.03 0.72 0.52 to 0.99 0.05
Born prematurely† – – – 1.97 1.18 to 3.28 0.01
Follow-up illness events
  Outpatient treatment for diarrhoea 1.68 1.15 to 2.44 0.007 – – – 
  Readmission to hospital for diarrhoea 1.91 1.02 to 3.55 0.04 – – – 
  Readmission to hospital for severe pneumonia 1.90 1.12 to 3.22 0.02 – – – 
*Compared with children with minimal change in HAZ (±0.25Z). HAZ difference is the difference between HAZ at month 12 and at study enrolment. 
†Gestational age <37 weeks. Relative risk ratios are computed using multinomial logistic regression with minimal HAZ change (−0.25 to 0.25Z) as the reference and adjusted for 
regression to the mean. All the factors examined in the multivariate multinomial logistic regression are reported on univariate analysis (online supplementary table 5). Here only 
factors with a p value <0.05 are presented; p values are from multivariable multinomial logistic regression.
HAZ, height/length-for-age z-score; RRR, relative risk ratio.
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countries, while diarrhoea was not a risk factor for poor linear 
growth, but presence of higher enteropathogen load in non-diar-
rhoea stools was associated with poor length growth.32 33
Although not examined in this study, environmental enteric 
dysfunction (EED) common in resource-poor countries has been 
suggested as additional factor impacting on linear growth.34 
EED is characterised by systematic inflammation of the small 
intestine, which is more frequent among children with SAM 
and likely to increase metabolic demands, altered nutrient 
processing by the microbiota and absorption, thereby affecting 
linear growth.35 36 Providing 81 Jamaican malnourished children 
with metronidazole to treat small intestinal bacterial over-
growth in addition to a high energy nutritional supplement 
improved both linear and weight growth compared with the 
supplement only.37 Metronidazole is now being tested in a large 
(n=2000) multicentre clinical trial among children with SAM 
(ISRCTN18051843).
The parent trial intervention, co-trimoxazole prophylaxis 
had a stabilising effect on HAZ, reducing both gain and loss. 
The mechanism for this is unclear but may reflect potential 
multiple effects of co-trimoxazole on infection, as well as on the 
gut microbiota involved in nutrient processing and absorption. 
Table 3 Multivariable analysis of association between HAZ change and changes in weight, WAZ, WHZ and MUAC during 1-year follow-up
Change between study enrolment and 
month 12
Correlation 
coefficient†
lost at least 0.25 hAZ* Gained at least 0.25 hAZ*
Adjusted rrr‡ 95% CI P values Adjusted rrr† 95% CI P values
Change in weight per  kg 0.55 0.46 0.39 to 0.56 <0.001 2.15 1.82 to 2.54 <0.001
Change in WAZ per z-score 0.61 0.44 0.35 to 0.55 <0.001 2.19 1.77 to 2.71 <0.001
Change in WHZ per z-score 0.15 0.80 0.69 to 0.92 0.002 1.10 0.95 to 1.27 0.19
Change in MUAC per cm 0.46 0.69 0.60 to 0.80 <0.001 1.46 1.28 to 1.68 <0.001
*Compared with children with minimal change in HAZ (±0.25Z).
†Spearman’s rank correlation coefficient.
‡Adjusted for co-trimoxazole randomisation arm, child carer, born premature (<37 weeks), height-for-age at study enrolment, outpatient treatment for diarrhoea and 
readmission during follow-up for diarrhoea. Relative risk ratios are computed using multinomial logistic regression with minimal HAZ change (−0.25 to 0.25Z) as the reference. 
P values from multivariable multinomial logistic regression.
HAZ, height/length-for-age z-score; MUAC, mid-upper arm circumference; RRR, relative risk ratio; WAZ, weight-for-age z-score; WHZ, weight-for-height/length z-score.
Figure 2 Scatter plots of change in HAZ with: (A) change in weight (kg) (p=0.25), (B) changes in WAZ (p=0.11), (C) change in WHZ (p=0.07), and 
(D) change in MUAC (cm) (p=0.24) with fitted fractional polynomial curves (95% CI). P values are from comparisons of model deviance between 
multiple fractional polynomial regression and linear regression models. HAZ, height/length-for-age z-score; MUAC, mid-upper arm circumference; 
WAZ, weight-for-age z-score; WHZ, weight-for-height/length z-score.
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Similarly, co-trimoxazole was associated with increased diar-
rhoea in the original trial, but reduced malaria, skin and urinary 
tract infections.23
Unlike findings from previous studies, after adjusting for 
other factors, age was not independently associated with HAZ 
changes.38–40 Children born prematurely had greater linear 
growth than their term peers in this study, reaching a similar 
HAZ to other children after 12 months of follow-up. However, 
typically preterm neonates may not fully catch up in length 
with full-term infants.41 Children not cared by their biological 
parents were mostly under the care of children’s homes where 
nutritional and emotional care may have promoted linear 
growth (sometimes this was initiated at the index admission by 
the hospitals’ social services when absence of a home carer was 
identified).
Pooled  and meta-analyses of numerous interventions to 
improve linear growth have demonstrated marginal efficacy.34 42 
Bhutta et al predicted that implementing all the evidence-based 
nutritional interventions would only reduce stunting by 20% 
globally.42 However, a trial in Ecuador has recently demonstrated 
that introduction of daily eggs during the weaning period (6–9 
months) reduced stunting by 47%.43 These results are encour-
aging, suggesting that protein quality over a prolonged period 
may be important and should be tested in different settings, 
including following treatment for SAM.
strengths and limitations
We systematically followed children for 1 year after inpatient 
treatment for complicated SAM, a longer period than most SAM 
studies.19 22 24 Being a clinical trial meant a higher level of clinical 
care and opportunities for linear growth gain that may not exist 
in routine care. We adjusted for the study intervention alloca-
tion in the multivariable regression analysis. A limitation of this 
study was selection bias because we could only analyse data from 
participants with length measurement at month 12. Although 
excluded children had similar baseline characteristics, those 
without a month 12 measurement because of death, withdrawal 
or not physically attending this visit may have been more likely 
to have linear growth deficit than included children because they 
were more often ill during follow-up (under follow-up events in 
table 1).
COnClusIOn
Overall, intensive treatment and nutritional rehabilitation 
did not resolve stunting among children with SAM. Although 
reaching a previously proposed threshold of absolute WHZ of 
−1.3 was associated with increased short-term linear growth, 
this was seen in a subset of children who were less wasted, more 
stunted and with less comorbidity at enrolment. Interventions 
that prevent illness and improve dietary quality over a longer 
period may provide opportunities to improve linear growth 
following SAM.
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